Soterix Medical Inc. announces receipt of allowance of claims from the U.S. Patent Office for an application covering their system and method of non-invasive neuromodulation using the proprietary High-Definition transcranial Direct Current Stimulation (HD-tDCS) platform. The claims cover a system and method including an array of electrodes positioned on the scalp and energized so as to achieve controlled brain current flow and targeting. The patent includes assemblies with three or more electrodes and embodiments for electrode shape, current control methods, and brain targeting. The patent recognizes the invention of HD-tDCS at The City College of New York by Dr. Marom Bikson and colleagues and is exclusively licensed to Soterix Medical Inc. that continues to innovate the platform. This invention of HD-tDCS cover any deployments of tDCS and other transcranial electrical stimulation waveforms (tES) using array of electrodes where the electrodes are positioned and energized to provide meaningful control of brain targeting.
“Since it was founded, Soterix Medical continues to be an innovation leader in non-invasive neuromodulation. Nowhere is this clear as with HD-tDCS. HD-tDCS is the only technology capable of true non-invasive neuromodulation, combining advantages of conventional transcranial Direct Current Stimulation and FDA approved transcranial Magnetic Stimulation. Scientists and clinicians already recognize Soterix Medical as the originator and leader in HD-tDCS, and this patent award further recognizes the origin of this amazing innovation.” Ongoing clinical trials with HD-tDCS span applications in Depression, Pain, Epilepsy, and Stroke Rehabilitation. Dr. Datta, CTO of Soterix Medical continues, “This patent continues to build on our success in securing intellectual property for our truly unique product and services pipeline targeted toward neurological and neuropsychiatric disorders. Our IP portfolio spans all critical aspects of non-invasive electrical stimulation with arrays, precisely because we invented and developed the devices, software, and electrodes needed to achieve required performance. Soterix Medical continues to work closely with the best clinical centers in the world in support of clinical trials with HD-tDCS.”
